FONAR Announces Fiscal 2013 3rd Quarter and Nine Month

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
FONAR Announces Fiscal 2013 3rd Quarter and Nine Month Earnings Report; Total Assets Double; 3rd Quarter Revenues Increase 22% and 7th Straight Quarter of $1.5 Million of Net Income

MELVILLE, NY--(Marketwired - May 15, 2013) - FONAR Corporation ( NASDAQ : FONR ), The Inventor of MR Scanning™, reported its 3rd quarter fiscal 2013 and nine month financial results today, for the period ended March 31, 2013. The Company's two industry segments are: Development, manufacturing and servicing of the UPRIGHT® Multi-Position™ MRI, and management of 23 Stand-Up® MRI, (UPRIGHT® MRI) centers.

Third Quarter Highlights

During the quarter the Company's subsidiary, HMCA, entered into an agreement with outside investors to acquire a 50.5% controlling interest in a newly formed limited liability company, Health Diagnostics Management, LLC (HDM). HMCA contributed $20.2 million to HDM and the group of outside investors contributed $19.8 million for its non-controlling membership interest. 

On March 5, 2013, HDM purchased from Health Diagnostics, LLC and certain of its subsidiaries (HD), a business managing 12 Stand-Up® MRI centers and two other scanning centers located in the states of New York and Florida.

With the purchase of HD, the Company increased total assets to $73.3 million at March 31, 2013. This compares to total assets of $33.6 million at June 30, 2012, an increase of 118%. Meanwhile, total liabilities increased to $38.3 million at March 31, 2013 as compared to $22.5 million on June 30, 2012, an increase of 70%. Stockholder's equity increased to $35.0 million at March 31, 2013 from $11.1 million on June 30, 2012, an increase of 216%. 

FONAR continued on its surge of profitable quarters where net income was greater than $1.5 million, climbing to seven straight quarters. The Company has had 13 straight quarters of income from operations. 

Revenues increased 22% to $11.6 million for the quarter ended March 31, 2013, an increase of 21% from $9.6 million for the preceding quarter ending December 31, 2012. The revenues for this quarter are the largest quarterly revenue since the Nation's 2008 financial crisis. Approximately $2.8 million of revenue was from the acquisition of HD.

Statement of Operations Items

Net income for the quarters ended March 31, 2013 and March 31, 2012 was $1.6 million. Net income for the nine months ended March 31, 2013 was $5.0 million, as compared to $5.1 million for the nine-month period ended March 31, 2012. Net income for the quarter ended March 31, 2013 included only 3 weeks of the net income of HDM which was acquired on March 5, 2013.

Income from operations for the quarters ended March 31, 2013 and March 31, 2012, was $1.6 million. Income from operations for the nine months ended March 31, 2013, was $5.2 million, as compared to $5.3 million, for the nine-month period ended March 31, 2012.

Total revenues, for the quarter ended March 31, 2013, increased 22% to $11.6 million, as compared to the quarter ended March 31, 2012, when total revenues were $9.5 million. Total revenues, for the nine months ended March 31, 2013, increased 8% to $30.8 million, as compared to the nine months ended March 31, 2012, when total revenues were $28.5 million.

Basic net income per common share for the quarter ended March 31, 2013, was $0.17, as compared to $0.21 for the quarter ended March 31, 2012. Diluted net income per common share for the quarter ended March 31, 2013, was $0.17, as compared to $0.20 for the quarter ended March 31, 2012.

Basic net income per common share for the nine months ended March 31, 2013, was $0.61, as compared to $0.71 for the nine months ended March 31, 2012. Diluted net income per common share for the nine months ended March 31, 2013, was $0.60, as compared to $0.69 for the nine months ended March 31, 2012.

Revenues from the HMCA management and other fees segment which manages the FONAR UPRIGHT® Multi-Position™ MRI diagnostic imaging centers, increased 42% to $7.4 million for the three months ended March 31, 2013, from $5.2 million for the three-month period ended March 31, 2012. In addition, revenues from a new category called Patient Revenue - Net were $965,000. Patient revenue represents revenues generated by the acquisition of HD on March 5, 2013.

Costs related to HMCA management and other fees segment for the three months ended March 31, 2013, were $3.5 million. For the three-month period ended March 31, 2012, costs were $3.3 million. Costs related to patient revenue - net were $791,000 for the quarter ended March 31, 2013.

Balance Sheet Items

Total assets doubled for the quarter ended March 31, 2013 to $73.3 million, a 118% increase, as compared to $33.6 million at June 30, 2012.

Total liabilities at March 31, 2013 were $38.3 million, a 70% increase as compared to $22.5 million at June 30, 2012.

Total current assets at March 31, 2013 were $39.7 million, a 54% increase as compared to $25.9 million at June 30, 2012.

At March 31, 2013, total cash and cash equivalents were $9.2 million, as compared to $12.0 million at June 30, 2012. This $2.8 million reduction was primarily due to the $6.2 million used in the acquisition of HDM.

Total current liabilities at March 31, 2013 were $24.3 million, a 15% increase as compared to $21.1 million at June 30, 2012.

Significant Events

The Company will hold its annual meeting on June 24, 2013. Dr. Raymond Damadian, president and chairman of FONAR Corporation, has issued his annual shareholder letter which can be seen on the Company's Web site at www.fonar.com/shareholder_letter.htm . 

On March 5, 2013, the Company and its subsidiary, Health Management Corporation of American (HMCA), acquired a majority interest (50.5%) in a newly formed limited liability company, Health Diagnostics Management (HDM). Prior to the acquisition, HMCA was managing 11 STAND-UP® MRI diagnostic centers -- 8 in New York and 3 in Florida, collectively completing 45,000 scans in 2012. In one giant step, HMCA grew by 14 MRI facilities under HMCA management -- 10 in New York and 4 in Florida, 12 of them equipped with STAND-UP® MRIs. Those 14 centers completed 68,000 MRI scans in 2012. Together the two groups of centers completed 113,000 scans in 2012, a strong indicator of the patient throughput run rate that is expected for HMCA going forward.

During the third quarter, the Company installed a new FONAR UPRIGHT®, Weight-Bearing, Multi-Position™ MRI in Texarkana, Texas. The Company has now installed 157 UPRIGHT® Multi-Position™ MRI scanners and they have performed approximately 2.75 million UPRIGHT® MRI scans worldwide.

On May 1, 2013, the Company repaid a portion of the Class A Stockholders capital contribution in the amount of $1.2 million. The Company's subsidiary, HMCA, now owns an 85% interest in Imperial Management Services. 

Management Commentary

Dr. Raymond Damadian, M.D., president and chairman of Fonar Corporation, said: "The acquisition of HDM is expected to be a significant source of profitability. With this acquisition we doubled the assets of the Company and tripled our stockholder's equity and book value. Funds were obtained for the $40 million acquisition from a commercial bank at a low interest rate."

"There are more reasons why this acquisition makes a lot of sense," continued Dr. Damadian. "By combining the resources of HMCA and HDM, we will enjoy the benefits of economies of scale, shared administrative and technical expertise and capabilities, and joint marketing strategies. HMCA's 11 STAND-UP® MRIs together with HDM's 12 form a network of 23 STAND-UP® MRIs, the largest in the world."

"Of course, we're not finished growing," said Dr. Damadian. "We will continue to pursue additional management contracts, primarily in New York and Florida."

"This past April 6 th we held ' Symposium 2013 ' in New York City. The symposium was called 'The Cranio-Cervical Syndrome (CCS): The Vulnerability of the Human Neck and Its Impact on Cerebrospinal Fluid (CSF) Flow'," said Dr. Damadian. "There is a pandemic dimension of injuries of the neck and head, including 1.2 million whiplash injuries each year in the United States, and the principal purpose of Symposium 2013 was to bring the existence of this Cranio-Cervical Syndrome to the medical community and general populace. We will publish, before year-end, a monograph containing the complete presentation of the eight faculty who presented at the conference. We will also place their presentations online."

"Our understanding of the Cranio-Cervical Syndrome (CCS) and the vulnerability of the human neck and its impact on cerebrospinal fluid (CSF) flow began with our research and findings on multiple sclerosis. On September 20, 2011, I and co-author, FONAR scientist David Chu, PhD., published a paper titled ' The Possible Role of Cranio-Cervical Trauma and Abnormal CSF Hydrodynamics in the Genesis of Multiple Sclerosis, ' in the journal Physiological Chemistry and Physics and Medical NMR (Sept. 20, 2011, 41: 1-17), found at http://www.fonar.com/ . With this new understanding of the role that cervical trauma plays in the etiology of disease, it is imperative to certify that the sustained neck or head injuries of professional athletes such as NFL football players, whiplash patients and others with severe neck trauma, have not resulted in any obstructions of CSF flow, which would eventually lead to the symptomatology we have reported as related to the Cranio-Cervical Syndrome," said Dr. Damadian.

"The Company is fortunate to have as its flagship product the FONAR UPRIGHT® Multi-Position™ MRI," continued Dr. Damadian. "This is truly a unique technology producing exquisite images in all positions of the body. It not only yields a whole new treasure of new medical applications in such calamitous medical categories as multiple sclerosis, and other dementia, but it also possesses the strong potential to provide fresh new insights into the debilitating chronic consequences of sports injuries, the current epidemic of automobile whiplash injuries, all spine injuries, and more diseases yet to be unearthed."

About FONAR

FONAR ( NASDAQ : FONR ), Melville, NY, The Inventor of MR Scanning™ , was incorporated in 1978, and is the first, oldest and most experienced MRI company in the industry. FONAR introduced the world's first commercial MRI in 1980, and went public in 1981. Since its inception, nearly 300 recumbent-OPEN MRIs and 157 UPRIGHT® Multi-Position™ MRI scanners have been installed worldwide. FONAR's stellar product is the UPRIGHT® MRI (also known as the Stand-Up® MRI), the only whole-body MRI that performs Position™ imaging ( p MRI™) and scans patients in numerous weight-bearing positions, i.e. standing, sitting, in flexion and extension, as well as the conventional lie-down position. The FONAR UPRIGHT® MRI often sees the patient's problem that other scanners cannot because they are lie-down only. The patient-friendly UPRIGHT® MRI has a near-zero claustrophobic rejection rate by patients. As a FONAR customer states, "If the patient is claustrophobic in this scanner, they'll be claustrophobic in my parking lot." Approximately 85% of patients are scanned sitting while they watch a 42" flat screen TV. FONAR is headquartered on Long Island, New York.

UPRIGHT® and STAND-UP® are registered trademarks and The Inventor of MR Scanning™ , Full Range of Motion™, Multi-Position™ , Upright Radiology™, The Proof is in the Picture™ , True Flow™, pMRI™ , Spondylography™, Dynamic™ , Spondylometry™, CSP™ , and Landscape™, are trademarks of FONAR Corporation.

This release may include forward-looking statements from the company that may or may not materialize. Additional information on factors that could potentially affect the company's financial results may be found in the company's filings with the Securities and Exchange Commission .

 
FONAR CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(000's OMITTED, except shares and per share data)
(UNAUDITED)
 
ASSETS
 
Current Assets:   March 31, 2013   June 30, 2012
Cash and cash equivalents   $ 9,243   $ 12,032
Accounts receivable - net     4,993     5,095
Accounts receivable - related party     30     -
Medical receivables - net     4,513     -
Management and other fees receivable - net     14,820     3,782
Management and other fees receivable - related medical practices - net     2,396      1,311
Costs and estimated earnings in excess of billings on uncompleted contracts     488     1,129
Inventories     2,284     2,195
Current portion of notes receivable - net     118     116
Prepaid expenses and other current assets     837     206
Total Current Assets     39,722     25,866
Property and equipment - net     17,713     3,173
Notes receivable     192     276
Goodwill     1,667     -
Other intangible assets - net     12,796     3,835
Other assets     1,191     465
Total Assets   $ 73,281   $ 33,615
             
LIABILITIES AND STOCKHOLDERS' EQUITY
 
Current Liabilities:   March 31, 2013   June 30, 2012
  Current portion of long-term debt and capital leases   $ 2,517   $ 1,854
  Accounts payable     2,639     2,077
  Other current liabilities     8,680     7,693
  Unearned revenue on service contracts     5,681     5,475
  Unearned revenue on service contracts - related party     28     -
  Customer advances     4,763     3,881
  Income tax payable     -     100
    Total Current Liabilities     24,308     21,080
Long-Term Liabilities:            
  Accounts payable, non current     -     47
  Due to related medical practices     231     229
  Long-term debt and capital leases, less current portion     13,404     777
  Other liabilities     362     401
    Total Long-Term Liabilities     13,997     1,454
    Total Liabilities     38,305     22,534
             
   
FONAR CORPORATION AND SUBSIDIARIES  
CONDENSED CONSOLIDATED BALANCE SHEETS  
(000's OMITTED, except shares and per share data)  
(UNAUDITED)  
LIABILITIES AND STOCKHOLDERS' EQUITY (Continued)  
   
LIABILITIES AND STOCKHOLDERS' EQUITY (continued) STOCKHOLDERS' EQUITY:   March 31, 2013     June 30, 2012  
Class A non-voting preferred stock $.0001 par value; 453,000 shares authorized at March 31, 2013 and June 30, 2012, 313,438 issued and outstanding at March 31, 2013 and June 30, 2012     -       -  
                 
Preferred stock $.001 par value; 567,000 shares authorized at March 31, 2013 and June 30, 2012, issued and outstanding - none     -       -  
                 
Common Stock $.0001 par value; 8,500,000 shares authorized at March 31, 2013 and June 30, 2012, 5,977,905 and 5,912,905 issued at March 31, 2013 and June 30, 2012, respectively; 5,966,262 and 5,901,262 outstanding at March 31, 2013 and June 30, 2012, respectively     1       1  
                 
Class B Common Stock (10 votes per share) $.0001 par value; 227,000 shares authorized at March 31, 2013 and June 30, 2012, 158 issued and outstanding at March 31, 2013 and June 30, 2012     -       -  
                 
Class C Common Stock (25 votes per share) $.0001 par value; 567,000 shares authorized at March 31, 2013 and June 30, 2012, 382,513 issued and outstanding at March 31, 2013 and June 30, 2012      -       -  
                 
Paid-in capital in excess of par value     174,478       174,084  
Accumulated other comprehensive loss     (15 )     (20 )
Accumulated deficit     (164,457 )     (168,334 )
Notes receivable from employee stockholders     (57 )     (71 )
Treasury stock, at cost - 11,643 shares of common stock at March 31, 2013 and June 30, 2012     (675 )     (675 )
Non controlling interests     25,701       6,096  
                 
Total Stockholders' Equity     34,976       11,081  
                 
Total Liabilities and Stockholders' Equity   $ 73,281     $ 33,615  
                 
   
FONAR CORPORATION AND SUBSIDIARIES  
CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED)  
(000's OMITTED, except shares and per share data)  
   
REVENUES   FOR THE THREE MONTHS ENDED MARCH 31,  
    2013     2012  
  Product sales - net   $ 416     $ 1,309  
  Service and repair fees - net     2,867       3,008  
  Service and repair fees - related parties - net     27       27  
  Patient revenue - net     965       -  
  Management and other fees - net     5,402       3,601  
  Management and other fees - related medical practices - net     1,965       1,571  
    Total Revenues - Net     11,642       9,516  
COSTS AND EXPENSES                
  Costs related to product sales     498       962  
  Costs related to service and repair fees     819       891  
  Costs related to service and repair fees - related parties     8       8  
  Costs related to patient revenue     791       -  
  Costs related to management and other fees     2,606       2,390  
  Costs related to management and other fees - related medical practices     900       953  
  Research and development     381       315  
  Selling, general and administrative     3,774       2,224  
  Provision for bad debts     235       170  
    Total Costs and Expenses     10,012       7,913  
Income From Operations     1,630       1,603  
Interest Expense     (79 )     (103 )
Investment Income     55       53  
Income Before Provision for Income Taxes     1,606       1,553  
Provision for Income Taxes     25       -  
Net Income     1,581       1,553  
Net Income - Non Controlling Interests     505       261  
Net Income - Controlling Interests   $ 1,076     $ 1,292  
Net Income Available to Common Stockholders   $ 1,005     $ 1,206  
Net Income Available to Class A Non-Voting Preferred Stockholders   $ 53     $ 64  
Net Income Available to Class C Common Stockholders   $ 18     $ 22  
Basic Net Income Per Common Share Available to Common Stockholders   $ 0.17     $ 0.21  
Diluted Net Income Per Common Share Available to Common Stockholders   $ 0.17     $ 0.20  
Basic and Diluted Income Per Share-Common C   $ 0.05     $ 0.06  
Weighted Average Basis Shares Outstanding     5,937,096       5,836,229  
Weighted Average Diluted Shares Outstanding     6,064,600       5,963,733  
Weighted Average Basic Shares Outstanding - Class C Common     382,513       382,513  
Weighted Average Diluted Shares Outstanding - Class C Common     382,513       382,513  
                 
   
FONAR CORPORATION AND SUBSIDIARIES  
CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED)  
(000's OMITTED, except shares and per share data)  
   
REVENUES   FOR THE NINE MONTHS ENDED MARCH 31,  
    2013     2012  
  Product sales - net   $ 2,536     $ 4,699  
  Service and repair fees - net     8,341       8,720  
  Service and repair fees - related parties - net     83       83  
  Patient revenue - net     965       -  
  Management and other fees - net     12,946       10,238  
  Management and other fees - related medical practices - net     5,895       4,712  
  Total Revenues - Net     30,766       28,452  
COSTS AND EXPENSES                
  Costs related to product sales     2,457       3,608  
  Costs related to service and repair fees     2,579       2,572  
  Costs related to service and repair fees - related parties     26       24  
  Costs related to patient revenue     791       -  
  Costs related to management and other fees     7,013       6,462  
  Costs related to management and other fees - related medical practices     2,568       2,673  
  Research and development     1,031       938  
  Selling, general and administrative     8,338       6,261  
  Provision for bad debts     735       655  
  Total Costs and Expenses     25,538       23,193  
Income From Operations     5,228       5,259  
Interest Expense     (258 )     (333 )
Investment Income     174       178  
Other (Expense) Income     (13 )     55  
Income Before Provision for Income Taxes     5,131       5,159  
Provision for Income Taxes     152       21  
Net Income     4,979       5,138  
Net Income - Non Controlling Interests     1,103       796  
Net Income - Controlling Interests   $ 3,876     $ 4,342  
Net Income Available to Common Stockholders   $ 3,621     $ 4,051  
Net Income Available to Class A Non-voting Preferred Stockholders   $ 190     $ 217  
Net Income Available to Class C Common Stockholders   $ 65     $ 74  
Basic Net Income Per Common Share Available to Common Stockholders   $ 0.61     $ 0.71  
Diluted Net Income Per Common Share Available to Common Stockholders   $ 0.60     $ 0.69  
Basic and Diluted Income Per Share-Common C   $ 0.17     $ 0.19  
Weighted Average Basic Shares Outstanding     5,921,540       5,744,506  
Weighted Average Diluted Shares Outstanding     6,049,044       5,872,010  
Weighted Average Basic Shares Outstanding - Class C Common     382,513       382,513  
Weighted Average Diluted Shares Outstanding - Class C Common     382,513       382,513  
                 

Contact: Daniel Culver Director of Communications FONAR Corporation Tel: 631-694-2929 Fax: 631-390-1709 http://www.fonar.com Email Contact

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Northern Jet Names Veteran Matthew Harris as CEO

Updated Category News Views 27

Fresh Leadership at Northern Jet Well, if you didn’t see this coming, you’ve been snoozing on the tarmac. Northern Jet, no stranger to the skies after three decades, just roped in Matthew Harris as their new CEO from October 2, 2026. They're pulling in this hotshot with more than 25 years riding the turbulence of private aviation. And listen to this: his marching...

Continue Reading
TA Services Strengthens U.S.-Mexico Freight Operations

Updated Category News Views 18

TA Services Moves Boldly Across Borders If ever there was a time to play the logistics chessboard like a champ, it's now, and TA Services just slammed the board with a solid move. They've grabbed Carmen Pacheco Transportation and Interload Forwarding, two family-run operations with some real muscle in North American logistics. This isn't a small-time maneuver; they've...

Continue Reading
Pushing for National Liver Cancer Awareness in 2026

Updated Category News Views 17

The Urgency of Liver Cancer Awareness Death doesn’t wait, does it? When liver cancer is the villain in question, every moment becomes precious because this beast doesn’t roar until it’s too late. Here we are in 2026, staring at nearly 31,000 annual deaths in the U.S. alone. But hope flickers with a new congressional resolution aiming to slap a bright spotlight on...

Continue Reading
NYSE Texas Redefines the U.S. Capital Markets Landscape

Updated Category News Views 17

NYSE Texas: Carving a Niche The notion of 'Y'all Street' might seem like a gimmick, but NYSE Texas is pushing a serious agenda with its newly released white paper, 'NYSE Texas and the Reshaping of U.S. Capital Markets.' This is no small feat. Texas is already housing 235 NYSE-listed companies, boasting a colossal combined worth of $4.8 trillion. With 130 of these firms...

Continue Reading
Purina Institute Highlights Nutritional Science at WSAVA 2026

Updated Category News Views 17

A Global Stage for Pet Nutrition Science The folks over at the Purina Institute are back in the spotlight as they gear up to throw their weight behind the 51st World Small Animal Veterinary Association (WSAVA) Congress in Warsaw, Poland. Set for October 13-15, 2026, this isn’t just another event—they're bringing some serious clout with their 'Food for Thought'...

Continue Reading
Cure Blindness Project's 770K Screenings for World Sight Day

Updated Category News Views 18

Visionary Steps Toward a Brighter Future No two words could describe the task that Cure Blindness Project is tackling this year: vision and action. Marking World Sight Day on October 8, they plan to usher in 770,000 eye screenings across Asia, Africa, and the Caribbean. These initiatives aren't just numbers—they're a colossal step toward lifting the veil of avoidable...

Continue Reading
Truss Financial Tackles Home Equity Closing Delays

Updated Category News Views 22

Truss Financial Group's Bold Move Against Closing Delays In real estate, time is money. Even the most casual market observer could tell you delays can slice through a deal like a hot knife through butter. That's the headache home equity borrowers face, blindsided by closing delays that sneak up on them without warning. An Industry Bottleneck Finally Addressed Enter Truss...

Continue Reading
Karoo Health Leaps Forward with New CCO Breton

Updated Category News Views 14

Change of Guard in Cardiac Health at Karoo Here's a move that might shake things up in the healthtech sector: Karoo Health just snagged Angela "Angie" Breton as their new Chief Commercial Officer. It's like putting a seasoned captain at the helm right before setting sail on uncharted waters. Breton's not just any captain—she's got a hefty 25 years of experience...

Continue Reading
Skandia's Soundproofing Kit Expands to Brazil's Skies

Updated Category News Views 13

Soundproofing Takes Off in Brazil Skandia has just pulled off a neat trick, earning the nod from Brazil's National Civil Aviation Agency (ANAC) for their King Air soundproofing kit. That means quieter skies ahead for operators of the King Air 200 and 300 series in Brazil. This is no small feat, folks; it's like finally getting that coveted backstage pass after years of...

Continue Reading
Bob Evans' Protein Mac & Cheese: Practical Power Play

Updated Category News Views 21

Has anyone else noticed just how fast the world spins when it comes to consumer trends these days? Bob Evans is hopping right on the protein bandwagon with its latest launch, a microwave-ready Protein Macaroni & Cheese that packs 18 grams of protein per serving. You gotta hand it to them for seizing opportunity when they see it. This one's not just about tossing a new...

Continue Reading

Top 5 Most Recently Viewed Articles

Eli Lilly's Muvalaplin Shows Significant Lipoprotein(a) Reduction

Updated Category News Views 300

Revolutionary Findings on Muvalaplin for Cardiovascular Health Positive Phase 2 Study Results Muvalaplin, an innovative oral treatment by Eli Lilly and Company, has demonstrated remarkable efficacy in lowering lipoprotein(a) levels, achieving reductions of up to 85% in adults at high risk for cardiovascular disease. This was highlighted in a recent 12-week Phase 2 study,...

Continue Reading
KT&G Unveils Ambitious Shareholder Return and Growth Strategy

Updated Category News Views 430

KT&G's Comprehensive Corporate Value-Up Plan KT&G Corporation, a leading player in the industry, has recently announced its ambitious Corporate Value-Up Plan aimed at enhancing shareholder returns and boosting its return on equity (ROE) targets. The plan outlines a robust strategy, with a remarkable KRW 3.7 trillion commitment to shareholders by the year 2027. Significant...

Continue Reading
Growth of Hexachlorodisilane Market Fueled by Semiconductor Needs

Updated Category News Views 101

Understanding the Hexachlorodisilane Market Growth The global hexachlorodisilane market is witnessing significant growth. According to recent studies, it was valued at $175.9 million in 2024 and is on track to reach an impressive $284.8 million by 2035. This expansion is forecasted to occur at a compound annual growth rate (CAGR) of 4.5%. Such a rise can largely be...

Continue Reading
Kishore Korde's Strategic Decision: $1.93M Sale in Air Lease Stock

Updated Category News Views 202

Kishore Korde's Strategic Decision: $1.93M Sale in Air Lease Stock Kishore Korde, Executive Vice President at Air Lease (NYSE: AL), executed a significant insider sale recently, which drew considerable attention among investors. According to the latest SEC filing, Korde sold 30,160 shares of Air Lease, amounting to a total value of $1,927,224. This sale suggests a...

Continue Reading
Celebrating Dental Hygiene and Orthodontics for Lifelong Smiles

Updated Category News Views 83

Importance of Dental Hygiene and Orthodontics In today's health-conscious society, the significance of dental hygiene and orthodontics has never been more apparent. Benevis, an esteemed dental healthcare organization, emphasizes the vital roles these practices play in maintaining comprehensive oral health. Celebrating the Happy, Healthy Smile Month, this initiative raises...

Continue Reading